Sumitomo Mitsui Trust Group Inc. Acquires 2,340 Shares of Charles River Laboratories International, Inc. $CRL

Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 109.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,481 shares of the medical research company’s stock after buying an additional 2,340 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Charles River Laboratories International were worth $680,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. Teacher Retirement System of Texas bought a new position in shares of Charles River Laboratories International during the 1st quarter valued at approximately $1,231,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Charles River Laboratories International by 15.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,118 shares of the medical research company’s stock valued at $952,000 after buying an additional 817 shares during the period. GAMMA Investing LLC lifted its position in Charles River Laboratories International by 61.6% in the first quarter. GAMMA Investing LLC now owns 1,398 shares of the medical research company’s stock worth $210,000 after buying an additional 533 shares during the last quarter. Concurrent Investment Advisors LLC purchased a new position in shares of Charles River Laboratories International during the 1st quarter worth about $213,000. Finally, GW&K Investment Management LLC grew its holdings in Charles River Laboratories International by 41.1% during the 1st quarter. GW&K Investment Management LLC now owns 88,410 shares of the medical research company’s stock valued at $13,307,000 after purchasing an additional 25,744 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CRL. Wall Street Zen lowered Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 23rd. Evercore ISI raised their target price on shares of Charles River Laboratories International from $190.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, October 3rd. William Blair raised shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a research note on Monday, October 6th. Barclays raised Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $165.00 to $195.00 in a research note on Thursday, October 2nd. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Charles River Laboratories International in a report on Wednesday, October 8th. Eight analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $181.29.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 800 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $157.60, for a total transaction of $126,080.00. Following the transaction, the executive vice president owned 24,116 shares in the company, valued at $3,800,681.60. This represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Price Performance

NYSE CRL opened at $180.17 on Friday. The firm’s fifty day simple moving average is $167.05 and its two-hundred day simple moving average is $152.66. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $230.02. The firm has a market capitalization of $8.87 billion, a P/E ratio of -135.46, a P/E/G ratio of 4.83 and a beta of 1.50.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The firm had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $983.76 million. During the same quarter last year, the firm earned $2.80 EPS. The business’s quarterly revenue was up .6% on a year-over-year basis. Analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).